As we roll towards the natural break in time that is the end of the year, we just couldn’t help but give in to the compulsion to cast our thoughts back through the last twelve months. Maybe we’ve got story-telling on the mind (this time of year does lend itself particularly well to tales by the fire)... in any case, we thought it would be fitting to recount the events that made up Micreos’ journey through 2016.
In a world where antibiotics are no longer suitable for sustained use, our bacteria-killing technology has put us at the forefront of the antibiotic alternative movement for skin conditions… and we’ve found it an exciting place to be.The year began with a double dose of developments. In February our ambition to develop Staphefekt, our endolysin-based proprietary technology, as a pharmaceutical product intended for treatment of new conditions was bolstered by securing €12 million in additional equity. Then in March we were hugely pleased to bring on board Dr Johan Frieling as our Chief Medical Officer, an industry leader in clinical development, the ideal person to oversee the progression of Staphefekt in new application areas.
As the year progressed, evidence for Staphylococcus aureus colonisation as a possible trigger for eczema mounted, with a systematic review of 95 studies published in the British Journal of Dermatology in July implicating the bacterium in the development and severity of the disease. We were excited by this news as it points to a need for a treatment that rebalances the skin microbiome by targeting S. aureus, which Staphefekt is specifically designed to do.
In September, we felt enormously encouraged by UN’s recognition of the serious threat that antimicrobial resistance poses, discussing the urgent need for sustained research and development to find antibiotic alternatives at the General Assembly, only the fourth time a health topic has ever been raised at this level. Our CEO, Mark Offerhaus emphasised that we are very much part of this fight in Industrial Pharmacy’s cover story that quarter.
Figure 1: Micreos featured on the front page of the quarter 3 Industrial Pharmacy Magazine
So as we reach the end of 2016, we find ourselves in the position to peer forward into 2017. In our efforts to prove the clinical efficacy of Gladskin and the benefits it could bring to eczema patients, Suzanne Pasmans, professor of pediatric dermatology at the Erasmus University Centre, leads our first clinical trial, due for completion mid-way through the year. With another potential round of funding in 2017, we hope to expand the development of our technology for future pharmaceutical products to combat atopic dermatitis, acne, rosacea, diabetic wounds, and prosthetic joint infections.
And finally, to kick this year off in style, we’re set to see Gladskin featured on the BBC’s Trust Me I’m a Doctor. Look out for us in the spotlight come January!